Kevin Kim, MD, Oncologist; Director of Clinical Research, CPMC’s Center for Melanoma Research and Treatment; CPMCRI Scientist

California Pacific CURRENTS: The online journal of CPMC Research Institute

Developing targeted therapies for the treatment of melanoma; advancing patient care through translational research

Research Overview

  • A prominent medical oncologist who is board-certified in internal medicine and medical oncology, Dr. Kevin Kim’s research interests are in melanoma, mucosal melanoma, and targeted therapies. He investigates targeted treatments based on molecular profiling of patients with metastatic melanoma. 
  • Collaborating with Dr. Mohammed Kashani-Sabet and others in the Center for Melanoma Research and Treatment, Dr. Kim is a Principal Investigator for National Cancer Institute and industry-sponsored phase 1 and 2 clinical trials investigating the biology of genetic mutations in melanoma, as well as new combinations of targeted and immunotherapies.
  • With extensive experience in translational melanoma research, Dr. Kim was an integral part of the early drug development of vemurafenib and dabrafenib (both BRAF inhibitors) and trametinib (a MEK inhibitor), which are now FDA-approved drugs for patients with V600BRAF-mutant metastatic melanoma.
  • With the advancement of these treatments and an expanding knowledge of biomarkers, Dr. Kim is focusing his efforts on bringing novel, more personalized therapies to patients.
  • As Director of Clinical Research in the melanoma group and in collaboration with Dr. Kashani-Sabet and others, Dr. Kim will help lead CPMC’s efforts to build a database and tumor bank of tissue samples from patients with melanoma; these will enable new tools to discover characteristics  of tumors in patients, to advance personalized therapies.
  • Dr. Kim has authored over 140 publications, book chapters, and abstracts on emerging treatments for melanoma. He has acted as a reviewer for high-impact journals including Clinical Cancer Research, Annals of Oncology, Journal of Clinical Oncology, and Cancer
  • Research and other initiatives at CPMC’s Center for Melanoma Research and Treatment have yielded five-year survival rates for metastatic melanoma that are double the national average.


Dr. Kim received his M.D. from the University of Illinois in Chicago. He completed residency training in internal medicine at the Mayo Clinic in Rochester, and a fellowship in medical oncology/hematology at the University of Texas MD Anderson Cancer Center. Dr. Kim was previously appointed as physician and professor at the University of Texas MD Anderson Cancer Center in Houston.


Publication Search


Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY, A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immunother

Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM, A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Invest New Drugs

LoRusso PM, Infante JR, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB, A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA, Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA, Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol

Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT, Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol

Kevin Kim, MD, Oncologist; Director of Clinical Research, CPMC’s Center for Melanoma Research and Treatment; CPMCRI Scientist
Primary Research Interests
  • Melanoma and mucosal melanoma
  • Immunotherapies and targeted therapies
  • Biomarker discovery
  • Tumor banking research